MA53541B1 - Dérivés hétéroaryles bicycliques - Google Patents
Dérivés hétéroaryles bicycliquesInfo
- Publication number
- MA53541B1 MA53541B1 MA53541A MA53541A MA53541B1 MA 53541 B1 MA53541 B1 MA 53541B1 MA 53541 A MA53541 A MA 53541A MA 53541 A MA53541 A MA 53541A MA 53541 B1 MA53541 B1 MA 53541B1
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic heteroaryl
- heteroaryl derivatives
- compounds
- methods
- derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne de nouveaux composés hétéroaryles bicycliques de formule générale (i), dans laquelle r1, ar, n et m sont tels que décrits dans la description, des compositions comprenant les composés, des procédés de fabrication des composés et des procédés d'utilisation des composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192219 | 2018-09-03 | ||
| PCT/EP2019/073303 WO2020048904A1 (fr) | 2018-09-03 | 2019-09-02 | Dérivés hétéroaryles bicycliques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53541A MA53541A (fr) | 2021-12-08 |
| MA53541B1 true MA53541B1 (fr) | 2024-02-29 |
Family
ID=63490310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53541A MA53541B1 (fr) | 2018-09-03 | 2019-09-02 | Dérivés hétéroaryles bicycliques |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US12084461B2 (fr) |
| EP (1) | EP3846903B1 (fr) |
| JP (1) | JP7398435B2 (fr) |
| KR (1) | KR102829709B1 (fr) |
| CN (1) | CN112566696B (fr) |
| AR (1) | AR116051A1 (fr) |
| AU (1) | AU2019336492B2 (fr) |
| BR (1) | BR112021002170A2 (fr) |
| CA (1) | CA3107593A1 (fr) |
| CL (1) | CL2021000486A1 (fr) |
| CO (1) | CO2021002415A2 (fr) |
| CR (1) | CR20210104A (fr) |
| DK (1) | DK3846903T3 (fr) |
| ES (1) | ES2966947T3 (fr) |
| FI (1) | FI3846903T3 (fr) |
| HR (1) | HRP20231663T1 (fr) |
| HU (1) | HUE064554T2 (fr) |
| IL (1) | IL281175B2 (fr) |
| LT (1) | LT3846903T (fr) |
| MA (1) | MA53541B1 (fr) |
| MX (1) | MX2021002087A (fr) |
| MY (1) | MY208133A (fr) |
| PE (1) | PE20210860A1 (fr) |
| PH (1) | PH12021550320A1 (fr) |
| PL (1) | PL3846903T3 (fr) |
| PT (1) | PT3846903T (fr) |
| RS (1) | RS64950B1 (fr) |
| SG (1) | SG11202102137SA (fr) |
| SI (1) | SI3846903T1 (fr) |
| TW (1) | TWI841592B (fr) |
| UA (1) | UA128482C2 (fr) |
| WO (1) | WO2020048904A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019412747B8 (en) | 2018-12-27 | 2025-04-24 | F. Hoffmann-La Roche Ag | Process for the preparation exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| EP1422217A3 (fr) | 1998-04-01 | 2004-06-16 | Cardiome Pharma Corp. | Composés aminocyclohexyle ether et leur utilisation |
| AU2528900A (en) | 1999-02-12 | 2000-08-29 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| AU5289600A (en) | 1999-05-25 | 2000-12-12 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
| WO2001032170A1 (fr) | 1999-09-13 | 2001-05-10 | Swope David M | Composition et procede pour la reduction de la symptomatologie neurologique |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| US8703753B2 (en) | 2005-09-15 | 2014-04-22 | Biomas Ltd. | Use of tellurium compounds for the treatment of actinic keratosis |
| RU2009140182A (ru) | 2007-05-11 | 2011-06-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Гетариланилины в качестве модуляторов для бета-амилоида |
| NZ584716A (en) | 2007-10-19 | 2011-12-22 | Janssen Pharmaceutica Nv | PIPERIDINYL AND PIPERAZINYL MODULATORS OF gamma-SECRETASE |
| RU2011123862A (ru) | 2008-11-13 | 2012-12-20 | Шеринг Корпорейшн | Модуляторы гамма-секретазы |
| CN102333777B (zh) * | 2009-02-26 | 2014-06-25 | 卫材R&D管理有限公司 | 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途 |
| WO2010138901A1 (fr) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés |
| JPWO2011007756A1 (ja) * | 2009-07-13 | 2012-12-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| CN102484127B (zh) | 2009-09-04 | 2015-07-15 | 惠普开发有限公司 | 基于混合金属价键化合物的记忆电阻 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| AU2012285931B2 (en) | 2011-07-15 | 2017-01-12 | Cellzome Limited | Novel substituted indole derivatives as gamma secretase modulators |
| US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| JP6831372B2 (ja) | 2015-09-09 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋ピペリジン誘導体 |
| JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| JP7111704B2 (ja) | 2016-11-01 | 2022-08-02 | エフ．ホフマン－ラ ロシュ アーゲー | 二環式ヘテロアリール誘導体 |
| WO2018087018A1 (fr) | 2016-11-08 | 2018-05-17 | F. Hoffmann-La Roche Ag | Phénoxytriazoles |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| WO2019141832A1 (fr) | 2018-01-22 | 2019-07-25 | F. Hoffmann-La Roche Ag | Dérivés de triazolo-azépine |
-
2019
- 2019-09-02 MA MA53541A patent/MA53541B1/fr unknown
- 2019-09-02 SG SG11202102137SA patent/SG11202102137SA/en unknown
- 2019-09-02 JP JP2021512272A patent/JP7398435B2/ja active Active
- 2019-09-02 EP EP19759411.2A patent/EP3846903B1/fr active Active
- 2019-09-02 CR CR20210104A patent/CR20210104A/es unknown
- 2019-09-02 CA CA3107593A patent/CA3107593A1/fr active Pending
- 2019-09-02 TW TW108131458A patent/TWI841592B/zh active
- 2019-09-02 DK DK19759411.2T patent/DK3846903T3/da active
- 2019-09-02 IL IL281175A patent/IL281175B2/en unknown
- 2019-09-02 PT PT197594112T patent/PT3846903T/pt unknown
- 2019-09-02 KR KR1020217006240A patent/KR102829709B1/ko active Active
- 2019-09-02 US US17/273,278 patent/US12084461B2/en active Active
- 2019-09-02 MX MX2021002087A patent/MX2021002087A/es unknown
- 2019-09-02 AR ARP190102494A patent/AR116051A1/es unknown
- 2019-09-02 LT LTEPPCT/EP2019/073303T patent/LT3846903T/lt unknown
- 2019-09-02 HR HRP20231663TT patent/HRP20231663T1/hr unknown
- 2019-09-02 SI SI201930682T patent/SI3846903T1/sl unknown
- 2019-09-02 UA UAA202101190A patent/UA128482C2/uk unknown
- 2019-09-02 AU AU2019336492A patent/AU2019336492B2/en active Active
- 2019-09-02 FI FIEP19759411.2T patent/FI3846903T3/fi active
- 2019-09-02 WO PCT/EP2019/073303 patent/WO2020048904A1/fr not_active Ceased
- 2019-09-02 BR BR112021002170-1A patent/BR112021002170A2/pt unknown
- 2019-09-02 RS RS20231189A patent/RS64950B1/sr unknown
- 2019-09-02 CN CN201980054254.2A patent/CN112566696B/zh active Active
- 2019-09-02 HU HUE19759411A patent/HUE064554T2/hu unknown
- 2019-09-02 ES ES19759411T patent/ES2966947T3/es active Active
- 2019-09-02 PL PL19759411.2T patent/PL3846903T3/pl unknown
- 2019-09-02 MY MYPI2021001098A patent/MY208133A/en unknown
- 2019-09-02 PE PE2021000165A patent/PE20210860A1/es unknown
-
2021
- 2021-02-15 PH PH12021550320A patent/PH12021550320A1/en unknown
- 2021-02-24 CO CONC2021/0002415A patent/CO2021002415A2/es unknown
- 2021-02-26 CL CL2021000486A patent/CL2021000486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55131B1 (fr) | Nouveaux composés hétérocycliques | |
| MA53219B1 (fr) | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase | |
| MA64323B1 (fr) | Inhibiteurs de nlrp3 | |
| WO2019035864A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
| MA49560B1 (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA38432A1 (fr) | Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine | |
| MA48594B1 (fr) | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a | |
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA32104B1 (fr) | Dérivés d'oxime en tant qu'inhibiteurs de hsp90 | |
| MA31597B1 (fr) | Nouveaux herbicides | |
| TNSN07393A1 (fr) | Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques | |
| MA30427B1 (fr) | Derives bicycliques utilises comme inhibiteurs de cetp | |
| HRP20070076A2 (en) | Pyrimidine derivatives | |
| MA37756A1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA31690B1 (fr) | Nouveaux fongicides | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
| MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA37942A2 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| MA47085B1 (fr) | Polymorphes | |
| MA47081A (fr) | Polymorphes |